Exosomes vs PDRN: Choosing the Right Regenerative Injectable for Your Patient
Two of the most clinically significant injectable categories in modern aesthetic medicine — polynucleotides/PDRN and exosomes — are frequently compared by practitioners trying to determine which to offer, which to prioritise for specific patients, and whether there is clinical value in using both. The comparison is worth making carefully, because the two treatments operate through genuinely different mechanisms, have different evidence bases, suit different patient profiles in some respects, and produce their best outcomes in different clinical contexts.
PDRN vs HA Skin Boosters: Which Is Right for Your Patient?
As PDRN (polydeoxyribonucleotide) products enter mainstream aesthetic practice, one of the most common questions practitioners ask is deceptively simple: for a given patient, should I use PDRN or a HA skin booster? The question is deceptive because it implies a binary choice where the more useful clinical framing is a spectrum — with most patients sitting somewhere in the middle where both could offer benefit, and the skill lying in knowing which mechanism addresses their dominant concern more directly.
Biorevitalisation Patient Selection and Realistic Outcomes
Skin booster treatments have one of the highest patient satisfaction rates in aesthetic medicine — when the right patient is treated, with the right product, and with appropriate outcome expectations established at consultation. They also have one of the most predictable routes to patient dissatisfaction: treating a patient whose concern is structural volume loss with a treatment that addresses skin quality, or promising 'glowing, radiant skin' to a patient whose primary visible concern is a fat hernation or significant volume deficit that biorevitalisation cannot address.
